Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Translating AAD/NPF Guidelines to Your Clinical Practice to Lower Cardiovascular Risk in Patients with Psoriasis
Description
The symposium focused on the association between psoriasis and cardiovascular disease, highlighting that many clinicians primarily educate patients on psoriasis without screening them for cardiovascular risk factors. Studies indicate that individuals with psoriasis have a significant risk of developing cardiovascular diseases, with the risk increasing with the severity of psoriasis. Research shows that the inflammatory processes of psoriasis overlap with those of atherosclerosis, leading to elevated cardiovascular risk. It is essential for dermatologists to integrate cardiovascular screenings, such as blood pressure and diabetes assessments, into practice, particularly for patients with moderate to severe psoriasis. A health care model involving care coordinators has been proposed, aiming to enhance patient education and manage cardiovascular risks effectively within this patient population. Initial pilot studies have showed promise in identifying and managing elevated cardiovascular risks among psoriasis patients, emphasizing the need for collaborative care strategies between dermatologists and other healthcare providers. The talk concluded by encouraging dermatologists to adopt comprehensive care approaches to improve patient outcomes and monitor associated risks effectively.
View moreConclusions
- Psoriasis significantly increases the risk of cardiovascular disease and other comorbidities.
- Patients with moderate to severe psoriasis face a heightened risk of major adverse cardiovascular events (MACE), comparable to those with rheumatoid arthritis.
- The severity of psoriasis correlates with increased mortality risks and life expectancy reductions.
- Standard screenings for cardiovascular risk factors are underutilized in patients with psoriasis.
- Incorporating a care coordinator model may enhance the management of cardiovascular risk in psoriasis patients.
- Current treatments for psoriasis do not uniformly reduce cardiovascular risk, and some therapies may pose increased risks.
- Patients with psoriasis require more intensive cardiovascular risk management, especially as they age.
- Kivelevitch D, et al. Circulation. 2017;136(3):277-280.
- Azfar RS, Gelfand JM. Curr Opin Rheum 2008;20:416-422.
- Takeshita M et al. J Am Acad Dermatol. 2017;76:393-403.
- Abuabara K, et al. Br. J. Dermatol. 2010; 163(3):586.
- Gelfand, J.M., et al. JAMA. 2006;296:1735.
- Gelfand, J.M., et al. J. Invest. Derm. 2009; 129:2411.
- Mehta, N.N., et al. Eur. Heart J. 2010; 31:1000.
- Azfar R, et al. Arch Derm 2012; 148:995-1000.
- Wan J, et al. BMJ 2013;347;f5691.
- Noe MH, et al. J Invest Dermatol. 2018;138(1):228-230.
- Wan MT, et al. J Am Acad Dermatol. 2018;78(2):315-322.e1.
- Gelfand JM et al. JAAD. 2019: 80(4):1073-1113.
- Cai R, et al. Int J Rheum Dis. 2023 Apr;26(4):625-637.
- González-Cantero A, et al. J Invest Dermatol. 2021 Apr 20:S0022-202X(21)01149-0.
- Ytterberg SR, et al. N Engl J Med. 2022;386(4):316-326.
- Shivani et al. Clinical Gastroenterology and Hepatology, 2023.